![Emily Hill](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 3 M $ al 31/08/2026
Emily Hill is currently Chief Financial Officer at Replimune, Inc. and Replimune Group, Inc., both positions starting in 2023.
Former roles include Director at Greenhill Humane Society SPCA, Director-Investor Relations at Warner Chilcott Plc from 2011 to 2012, Senior Manager-Investor Relations at Genzyme Corp.
from 2008 to 2010, SVP & Head-Investor Relations at PTC Therapeutics, Inc. from 2018 to 2019, and Associate-Biotech Equity Research at Summer Street Capital Partners LLC.
Education includes an undergraduate degree from Hamilton College (New York) in 2002, a graduate degree from Tufts University School of Medicine in 2006, and an MBA from Fordham Gabelli School of Business in 2011.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,23 % | 17/08/2026 | 215.852 ( 0,23 % ) | 3 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| REPLIMUNE GROUP, INC. | Director Financiero/CFO | 19/09/2023 |
Replimune, Inc.
 Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Director Financiero/CFO | 01/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Warner Chilcott Plc
 Warner Chilcott Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Contacto de Relaciones con Inversores | 01/11/2012 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Contacto de Relaciones con Inversores | 01/01/2010 |
Summer Street Capital Partners LLC
 Summer Street Capital Partners LLC Investment ManagersFinance Summer Street Capital Partners invests in companies located in the United States and Canada. The firm focuses on companies operating in the fields of diverse industries with a particular interest in the niche manufacturing business & industrial services, distribution and environmental sectors. It provides financing for buyouts, MBOs, growth capital, family transitions, corporate divestitures and recapitalization transactions. | Corporate Officer/Principal | - |
| PTC THERAPEUTICS, INC. | Director Financiero/CFO | - |
Greenhill Humane Society SPCA
 Greenhill Humane Society SPCA Miscellaneous Commercial ServicesCommercial Services Provides shelter for animals | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Hamilton College (New York)
 Hamilton College (New York) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Summer Street Capital Partners LLC
Summer Street Capital Partners LLC Investment ManagersFinance Summer Street Capital Partners invests in companies located in the United States and Canada. The firm focuses on companies operating in the fields of diverse industries with a particular interest in the niche manufacturing business & industrial services, distribution and environmental sectors. It provides financing for buyouts, MBOs, growth capital, family transitions, corporate divestitures and recapitalization transactions. | Finance |
Greenhill Humane Society SPCA
Greenhill Humane Society SPCA Miscellaneous Commercial ServicesCommercial Services Provides shelter for animals | Commercial Services |
Warner Chilcott Plc
Warner Chilcott Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Tufts University School of Medicine
 Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Replimune, Inc.
Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Commercial Services |
Fordham Gabelli School of Business
 Fordham Gabelli School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
